PURPOSE: Familial renal cell carcinoma (RCC) is genetically heterogeneous. The most common histopathologic subtype of sporadic and familial RCC is clear cell (cRCC) and von Hippel-Lindau (VHL) disease is the most common cause of inherited cRCC. Familial cRCC may also be associated with chromosome 3 translocations and has recently been described in patients with Birt-Hogg-Dube (BHD) syndrome, caused by germline FLCN mutation. Fewer than 20 kindreds with familial cRCC without VHL disease or a constitutional translocation have been described. The purpose of this investigation was to define the clinical and genetic features of familial non-VHL cRCC (FcRCC) and to evaluate whether unrecognized BHD syndrome might be present in patients with apparent nonsyndromic RCC susceptibility. EXPERIMENTAL DESIGN: We analyzed the clinical features of, and undertook segregation analysis in, 60 kindreds containing two or more cases of RCC (at least one confirmed case of cRCC) and no evidence of an RCC susceptibility syndrome. We also undertook FLCN analysis to evaluate whether unrecognized BHD syndrome might be present in 69 patients with apparent nonsyndromic RCC susceptibility. RESULTS: FcRCC was characterized by an earlier age at onset than sporadic cases and more frequent occurrence of bilateral or multicentric tumors. Segregation analysis showed autosomal dominant inheritance with sex- and age-dependent penetrance. A germline FLCN mutation was detected in 3 of 69 (4.3%) patients with apparent nonsyndromic RCC susceptibility. CONCLUSIONS: We describe the clinical and genetic features of the largest series of FcRCC and recommend these patients be offered FLCN analysis, in addition to constitutional cytogenetic and VHL analysis.
PURPOSE:Familial renal cell carcinoma (RCC) is genetically heterogeneous. The most common histopathologic subtype of sporadic and familial RCC is clear cell (cRCC) and von Hippel-Lindau (VHL) disease is the most common cause of inherited cRCC. Familial cRCC may also be associated with chromosome 3 translocations and has recently been described in patients with Birt-Hogg-Dube (BHD) syndrome, caused by germline FLCN mutation. Fewer than 20 kindreds with familial cRCC without VHL disease or a constitutional translocation have been described. The purpose of this investigation was to define the clinical and genetic features of familial non-VHL cRCC (FcRCC) and to evaluate whether unrecognized BHD syndrome might be present in patients with apparent nonsyndromic RCC susceptibility. EXPERIMENTAL DESIGN: We analyzed the clinical features of, and undertook segregation analysis in, 60 kindreds containing two or more cases of RCC (at least one confirmed case of cRCC) and no evidence of an RCC susceptibility syndrome. We also undertook FLCN analysis to evaluate whether unrecognized BHD syndrome might be present in 69 patients with apparent nonsyndromic RCC susceptibility. RESULTS: FcRCC was characterized by an earlier age at onset than sporadic cases and more frequent occurrence of bilateral or multicentric tumors. Segregation analysis showed autosomal dominant inheritance with sex- and age-dependent penetrance. A germline FLCN mutation was detected in 3 of 69 (4.3%) patients with apparent nonsyndromic RCC susceptibility. CONCLUSIONS: We describe the clinical and genetic features of the largest series of FcRCC and recommend these patients be offered FLCN analysis, in addition to constitutional cytogenetic and VHL analysis.
Authors: Maria Rossing; Anders Albrechtsen; Anne-Bine Skytte; Uffe B Jensen; Lilian B Ousager; Anne-Marie Gerdes; Finn C Nielsen; Thomas vO Hansen Journal: J Hum Genet Date: 2016-10-13 Impact factor: 3.172
Authors: Kristi L Bennett; Rebecca Campbell; Shireen Ganapathi; Ming Zhou; Brian Rini; Ram Ganapathi; Hartmut P H Neumann; Charis Eng Journal: Genes Chromosomes Cancer Date: 2011-05-16 Impact factor: 5.006
Authors: Michael S Nahorski; Laurence Seabra; Ania Straatman-Iwanowska; Aileen Wingenfeld; Anne Reiman; Xiaohong Lu; Jeff A Klomp; Bin T Teh; Mechthild Hatzfeld; Paul Gissen; Eamonn R Maher Journal: Hum Mol Genet Date: 2012-09-10 Impact factor: 6.150
Authors: R S Preston; A Philp; T Claessens; L Gijezen; A B Dydensborg; E A Dunlop; K T Harper; T Brinkhuizen; F H Menko; D M Davies; S C Land; A Pause; K Baar; M A M van Steensel; A R Tee Journal: Oncogene Date: 2010-11-08 Impact factor: 9.867
Authors: Fred H Menko; Paul C Johannesma; R Jeroen A van Moorselaar; Rinze Reinhard; Jan Hein van Waesberghe; Erik Thunnissen; Arjan C Houweling; Edward M Leter; Quinten Waisfisz; Martijn B van Doorn; Theo M Starink; Pieter E Postmus; Barry J Coull; Maurice A M van Steensel; Johan J P Gille Journal: Fam Cancer Date: 2013-09 Impact factor: 2.375